Keros Therapeutics, Inc. 8-K

What Happened

• Keros Therapeutics, Inc. (KROS) filed a Current Report on Form 8-K on February 18, 2026 announcing that President and CEO Jasbir Seehra will participate in three upcoming investor presentations:
  • Oppenheimer 36th Annual Healthcare Life Sciences Conference — Wednesday, February 25, 2026 at 11:20 a.m. Eastern
  • TD Cowen 46th Annual Health Care Conference (fireside chat) — Tuesday, March 3, 2026 at 9:50 a.m. Eastern
  • Leerink Partners Global Healthcare Conference (fireside chat) — Tuesday, March 10, 2026 at 1:00 p.m. Eastern
• The company furnished a press release announcing these events (Exhibit 99.1). The disclosure was furnished under Regulation FD and is expressly noted as not being “filed” for purposes of Section 18 of the Exchange Act.

Key Details

• CEO: Jasbir Seehra is the scheduled presenter at all three events.
• Dates/times: Feb 25, 2026 at 11:20 a.m. ET; Mar 3, 2026 at 9:50 a.m. ET; Mar 10, 2026 at 1:00 p.m. ET.
• Filing: Information was furnished on Form 8-K (Regulation FD disclosure); press release attached as Exhibit 99.1.
• Legal note: The information is furnished (not filed) and is not incorporated by reference into other SEC filings unless explicitly stated.

Why It Matters

• These scheduled presentations give investors and analysts direct, public access to Keros’ CEO for updates on strategy, pipeline progress, and company developments.
• Because the announcement was made under Regulation FD via a Form 8-K, Keros aimed to broadly disclose this material investor outreach on a standardized SEC filing. Investors who follow the company may want to note the dates and check for any published materials or recordings from the conferences.